• Je něco špatně v tomto záznamu ?

Cost of severe hypoglycaemia in nine European countries

M. Jakubczyk, I. Lipka, J. Pawęska, M. Niewada, E. Rdzanek, J. Zaletel, A. Ramírez de Arellano, T. Doležal, B. Chekorova Mitreva, B. Nagy, G. Petrova, T. Šarić, J. Yfantopoulos, M. Czech,

. 2016 ; 19 (10) : 973-82. [pub] 20160603

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031753

OBJECTIVE: Complications contribute largely to the economic gravity of diabetes mellitus (DM). How they arise and are treated differs substantially between countries. This paper assesses the total annual, direct, and indirect cost of severe hypoglycemia events (SHEs) in nine European countries: Bulgaria, Croatia, the Czech Republic, Greece, Hungary, Macedonia/the former Yugoslav Republic of Macedonia (MK), Poland, Slovenia, and Spain. METHODS: Data was collected on epidemiology, treatment structure, SHE-driven resource consumption, and unit costs. Two systematic reviews-on the SHE rates and the resources used for treatment-and data on the days-of-work lost due to SHE along with salaries and employment rates were used. The total SHE cost in each country was calculated and how the differences are driven by individual parameters was analysed. RESULTS: The annual costs of SHEs varied in absolute terms from €379,951.25 in MK up to €58,429,684.40 in Spain, or-when expressed per one drug-treated DM patient-from €5.47 in Bulgaria up to €17.74 in Spain. Indirect cost constituted between 6.01% (MK) and 26.49% (Hungary) of the total cost. The differences between countries are driven mostly by the cost of treating a single event, and this is related to general differences in prices. LIMITATIONS: The main limitation is the lack of good quality data in some parts, and the necessity to use mean-value imputations, experts' opinions, etc. Additionally, we only considered DM treatment as the SHE driver, while other elements, e.g. style of living, may contribute substantially. CONCLUSIONS: A common framework can be applied to estimate the economic burden of SHE in various countries, allowing one to identify the drivers of differences in cost. Treating DM is complex, and so no resolute conclusions ought to be drawn as to whether SHE management is better in one country than another.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031753
003      
CZ-PrNML
005      
20171128143811.0
007      
ta
008      
171025s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/13696998.2016.1188823 $2 doi
035    __
$a (PubMed)27163169
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Jakubczyk, Michał $u a Decision Analysis and Support Unit, Warsaw School of Economics , Poland ;
245    10
$a Cost of severe hypoglycaemia in nine European countries / $c M. Jakubczyk, I. Lipka, J. Pawęska, M. Niewada, E. Rdzanek, J. Zaletel, A. Ramírez de Arellano, T. Doležal, B. Chekorova Mitreva, B. Nagy, G. Petrova, T. Šarić, J. Yfantopoulos, M. Czech,
520    9_
$a OBJECTIVE: Complications contribute largely to the economic gravity of diabetes mellitus (DM). How they arise and are treated differs substantially between countries. This paper assesses the total annual, direct, and indirect cost of severe hypoglycemia events (SHEs) in nine European countries: Bulgaria, Croatia, the Czech Republic, Greece, Hungary, Macedonia/the former Yugoslav Republic of Macedonia (MK), Poland, Slovenia, and Spain. METHODS: Data was collected on epidemiology, treatment structure, SHE-driven resource consumption, and unit costs. Two systematic reviews-on the SHE rates and the resources used for treatment-and data on the days-of-work lost due to SHE along with salaries and employment rates were used. The total SHE cost in each country was calculated and how the differences are driven by individual parameters was analysed. RESULTS: The annual costs of SHEs varied in absolute terms from €379,951.25 in MK up to €58,429,684.40 in Spain, or-when expressed per one drug-treated DM patient-from €5.47 in Bulgaria up to €17.74 in Spain. Indirect cost constituted between 6.01% (MK) and 26.49% (Hungary) of the total cost. The differences between countries are driven mostly by the cost of treating a single event, and this is related to general differences in prices. LIMITATIONS: The main limitation is the lack of good quality data in some parts, and the necessity to use mean-value imputations, experts' opinions, etc. Additionally, we only considered DM treatment as the SHE driver, while other elements, e.g. style of living, may contribute substantially. CONCLUSIONS: A common framework can be applied to estimate the economic burden of SHE in various countries, allowing one to identify the drivers of differences in cost. Treating DM is complex, and so no resolute conclusions ought to be drawn as to whether SHE management is better in one country than another.
650    12
$a osobní újma zaviněná nemocí $7 D017281
650    12
$a náklady a analýza nákladů $7 D003365
650    _2
$a Evropa $7 D005060
650    _2
$a náklady na zdravotní péči $x trendy $7 D017048
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemie $x ekonomika $x patologie $7 D007003
650    _2
$a stupeň závažnosti nemoci $7 D012720
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lipka, Izabela $u b HealthQuest spółka z ograniczoną odpowiedzialnością Sp. K , Warsaw , Poland ;
700    1_
$a Pawęska, Justyna $u b HealthQuest spółka z ograniczoną odpowiedzialnością Sp. K , Warsaw , Poland ;
700    1_
$a Niewada, Maciej $u c Department of Experimental and Clinical Pharmacology , Medical University of Warsaw , Poland ;
700    1_
$a Rdzanek, Elżbieta $u b HealthQuest spółka z ograniczoną odpowiedzialnością Sp. K , Warsaw , Poland ;
700    1_
$a Zaletel, Jelka $u d Department of Endocrinology, Diabetes and Metabolic Diseases , University Medical Centre , Ljubljana , Slovenia ;
700    1_
$a Ramírez de Arellano, Antonio $u e Novo Nordisk Pharma , Spain ;
700    1_
$a Doležal, Tomáš $u f Institute of Health Economics and Technology Assessment , Prague , the Czech Republic ; g Department of Pharmacology, 2nd Faculty of Medicine , Prague , the Czech Republic ;
700    1_
$a Chekorova Mitreva, Biljana $u h Novo Nordisk Pharma, Macedonia, the former Yugoslav Republic of Macedonia ;
700    1_
$a Nagy, Bence $u i Healthware Consulting Ltd , Budapest , Hungary ;
700    1_
$a Petrova, Guenka $u j Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy , Medical University of Sofia , Bulgaria ;
700    1_
$a Šarić, Tereza $u k Promeritus savjetovanje Ltd. , Zagreb , Croatia ;
700    1_
$a Yfantopoulos, John $u l School of Economics and Political Science , University of Athens , Greece ;
700    1_
$a Czech, Marcin $u m Department of Pharmacoeconomics , Medical University of Warsaw , Poland ; n Business School, Warsaw University of Technology , Poland.
773    0_
$w MED00193522 $t Journal of medical economics $x 1369-6998 $g Roč. 19, č. 10 (2016), s. 973-82
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27163169 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171128143939 $b ABA008
999    __
$a ok $b bmc $g 1255346 $s 992780
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 19 $c 10 $d 973-82 $e 20160603 $i 1369-6998 $m Journal of medical economics $n J Med Econ $x MED00193522
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace